Trial Profile
A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 04/04/2012), according to European Clinical Trials Database record.
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 21 Apr 2012 Planned number of patients changed from 80 to 99 as reported by European Clinical Trials Database.